Mazdutide

What it is (in plain language)
- While Semaglutide only acts on one receptor (GLP-1), Mazdutide acts on two. The GLP-1 component reduces appetite and improves insulin sensitivity, while the Glucagon component increases energy expenditure and fat burning in the liver. It's a 'dual action' approach to forcing the body to expend more energy while eating less.

Why do you appear online so much
- It is seen as the potential successor to Tirzepatide. Preliminary data suggests even more profound weight loss, especially in the reduction of hepatic fat (fatty liver), making it the new 'darling' of research into morbid obesity and extreme metabolic health.

How it is framed today (pragmatic view)
- 1) Evidence: Phase II clinical trials show superior results to simple agonists. 2) Objective: Treatment of obesity and non-alcoholic steatohepatitis (NASH). 3) Risk: Requires heart rate monitoring due to the glucagon component.

How to use this form
- Analyse the comparison between 'Single vs Dual Agonists' in the effectiveness section.

- Quick profile (curated by Subject 157)
- Class: Metabolic
- Status: Verified
- Use case: Fat Loss
- Route: Injectable
- Tags: Injectable|Fat Loss|Experimental
- Half-life: ~7 Days
- Start: 24-48 hours
- Duration: 7 days

- Mechanism (high level)
Activates GLP-1 (satiety) and Glucagon (GCGR) receptors. Glucagon activation increases energy expenditure and fat burning in the liver.

- Evidence (what the literature covers)
INVESTIGATION RANGE (Phase 2/3, Non-prescriptive):
Innovent Biologics.
Level of Evidence: B.

- Safety and harm-reduction (non-prescriptive)
Risks: Increased heart rate (Glucagon effect).
Nausea.
Arrhythmias (potential).
Interactions: Cardiotonics.

- References (anchors)
- Ji, L. (2023) - Mazdutide (IBI362) phase 2 trial (obesity / metabolic outcomes) - https://doi.org/10.2337/dc23-1287
- PubMed:37943529

Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.